Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to ...
Pulmonx Corporation (Nasdaq: LUNG) ('Pulmonx”), a global leader in minimally invasive treatments for lung disease, today ...
Pulmonx (NASDAQ:LUNG) executives said the company is entering 2026 focused on rebuilding U.S. momentum, advancing clinical programs designed to expand its total addressable market, and tightening ...
Net loss in the fourth quarter of 2025 was $10.4 million, or $0.25 per share, compared to a net loss of $13.2 million, or $0.33 per share, for the same period in 2024. Adjusted EBITDA loss in the ...
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that ...
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript March 4, 2026 Pulmonx Corporation beats earnings ...
Pulmonx Corp (LUNG) focuses on cost efficiency and sales team optimization to drive future growth despite current revenue declines.
7d
Pulmonx outlines 2026 revenue target of $90M-$92M with cost realignment and renewed U.S. sales focus
Q4 2025 earnings call recap: 2026 revenue guidance, cost cuts, sales force reset, and AeriSeal trial update—get key takeaways now.
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial ...
Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results